Clinically, gliomas with BRAF p.Val600Glu (V600E) mutations have shown responsiveness to molecularly targeted treatments, as demonstrated in trials for pediatric gliomas [15], and may be associated with a slightly better prognosis in certain contexts [17]. The gene discussed is BRAF; the disease is central nervous system cancer.